CarTrade Tech jumps 8% as Q4 profit rises 54% in FY26

Stocks advance despite a weak broader market

Shares of CarTrade Tech Ltd, Concord Biotech and Apar Industries rose as much as 8% in midweek trade even as the broader market was in a corrective phase. The gains were driven by a mix of company-specific triggers ranging from a brokerage upgrade to a regulatory approval and quarterly earnings.

CarTrade Tech was the most actively discussed name, with the stock reacting both to a positive brokerage view and to record annual earnings commentary from the company. Concord Biotech moved higher after it announced an approval from the US Food and Drug Administration (USFDA). Apar Industries’ move followed its fourth-quarter FY26 results, which showed an increase in revenue and a marginal rise in profit.

CarTrade Tech rallies on Kotak Institutional Equities upgrade

CarTrade Tech shares rose 8% to Rs 1,931 in early deals against a previous close of Rs 1,795.20. The company’s market capitalisation was reported at Rs 9,207 crore.

The immediate trigger for the early rise was a change in stance by Kotak Institutional Equities. The brokerage upgraded CarTrade Tech to “buy” from “sell” and raised its price target to Rs 2,300 per share from Rs 1,800, a 27.7% increase.

Kotak said CarTrade’s deep dealer database and value-added offerings could cap the effect of AI models to an extent. The brokerage also linked the upgrade to a sharply higher valuation for OLX, citing an expectation of steady gross merchandise value (GMV) growth, improving monetisation and margins.

Results-driven momentum adds to the move

CarTrade Tech’s rally also found support from the company’s quarterly and annual earnings narrative, as separate updates around the same period pointed to strong profitability growth. In another session, the stock was seen trading at around Rs 1,942 in late morning trade, up 7.5% for the day after extending gains post results.

CarTrade Tech said FY26 was a “landmark year” and that it delivered its highest-ever annual revenue, profit and margins. The company attributed the performance to execution across its Consumer Group, remarketing and OLX India businesses.

Market reactions referenced sharp profitability expansion in Q4 FY26, including a 54% year-on-year rise in profit and 17% year-on-year growth in revenue. Separately, another update cited standalone net profit for the quarter ended March 2026 at Rs 35.17 crore, up 64% year-on-year.

Intraday volatility: day highs and follow-through sessions

Price action around the results window showed strong intraday moves. One data point noted the stock jumping nearly 17% to touch a day’s high of Rs 2,120 following the announcement of numbers for the quarter ended March 31, 2026.

The stock was also described as extending gains into a second session, up about 5% on the day in that follow-on trade. Another update said the shares rebounded in May, gaining 18% after being under pressure for a prolonged period.

These moves underline how quickly sentiment can shift in a stock when earnings commentary, brokerage rating changes and the market’s view of acquired assets such as OLX India converge.

Concord Biotech rises after USFDA approval

Concord Biotech stock gained 8.36% to Rs 1,264.45 after the company said it received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.

The company described mycophenolate mofetil as an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult and pediatric recipients three months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

In Indian pharma stocks, USFDA-related updates often matter because they can expand addressable markets and validate manufacturing and compliance processes. In this case, the market response was immediate, with the stock moving higher on the approval headline.

Apar Industries climbs after Q4 FY26 performance update

Apar Industries’ move came after it announced consolidated financial results for the fourth quarter of FY26. The company reported net profit of Rs 253 crore, up 1.2% compared with Rs 250 crore in the same period last year.

Revenue from operations rose 26.74% year-on-year to Rs 6,602.81 crore on a consolidated basis. The figures positioned Apar as the third key stock in focus during the session alongside CarTrade Tech and Concord Biotech.

While the profit increase was modest, the revenue growth number stood out, and that was part of the context for the stock’s strength on the day.

Key data points at a glance

CarTrade operating scale mentioned in market updates

Apart from the financial metrics, trading commentary around CarTrade Tech also referenced operating scale. One update cited “540+ sites” and “76M monthly visitors” as part of the broader business footprint.

While these metrics do not replace financial performance, they are often used by the market to contextualise the reach of digital auto platforms and adjacent services. In CarTrade Tech’s case, the discussion also linked back to execution across business lines, including OLX India.

Why these triggers mattered for investors

Across the three names, the market reaction followed a pattern typical of event-driven moves in Indian equities. For CarTrade Tech, a brokerage upgrade combined with earnings-linked profitability expansion can lead to fast re-rating discussions, particularly when the target price is raised sharply.

For Concord Biotech, a USFDA approval is a discrete, verifiable event that can change near-term sentiment because it relates directly to product authorisations in a key market. For Apar Industries, the focus was on revenue growth in the reported quarter, with profitability showing a smaller year-on-year change.

The common thread was that each stock’s move was tied to a specific catalyst, even as the broader market tone was described as corrective.

Conclusion

CarTrade Tech, Concord Biotech and Apar Industries outperformed on the day on the back of clearly defined triggers: a Kotak rating upgrade and higher target price for CarTrade, USFDA approval news for Concord, and Q4 FY26 earnings for Apar. For CarTrade Tech, attention remained on the durability of margin expansion and how the market values OLX India alongside the core platform businesses. Investors are likely to track follow-up commentary around execution across business segments, and any further broker revisions or regulatory updates tied to these companies.